Ural Federal University Expert Honoured With The Butlerov Gold Medal
Oleg Chupakhin, Academician of the Russian Academy of Sciences, Professor of the Department of Organic and Biomolecular Chemistry of the Ural Federal University, has been awarded the Butlerov Prize. His outstanding scientific works on C-H functionalization of organic compounds, which are of great scientific and practical importance, have received worldwide recognition and have determined the development of organic chemistry and the practice of modern organic synthesis.
His candidacy was proposed by RAS academicians Oleg Sinyashin and Valery Charushin. According to the results of the secret ballot, a resolution on awarding the Gold Medal to Oleg Chupakhin was unanimously submitted to the Presidium of the RAS.
Oleg Chupakhin, Academician of the Russian Academy of Sciences, is a world-class scientist, one of the brightest leaders of the Ural School of Organic Chemists, whose works are internationally recognized and make a great contribution to the development of the theory and practice of organic chemistry. Chupakhin is the author and co-author of more than 600 scientific works, including 10 monographs, more than 200 certificates and patents. His students include more than 50 PhD and 13 Doctor of Science candidates.
In 1957 Oleg Chupakhin graduated with honors from the Ural Polytechnic Institute (now UrFU). In 1962 he defended his doctoral thesis, and in 1976 he defended his PhD thesis. His research interests include the chemistry of heterocyclic compounds, nucleophilic aromatic substitution of hydrogen, and medicinal chemistry. Chupakhin created a new scientific direction, which is reflected in modern textbooks of organic chemistry: theory and practical application of reactions of nucleophilic aromatic substitution of hydrogen. Modern directions – supramolecular chemistry and asymmetric synthesis of enantiomerically pure compounds – are developed. Synthetic antibiotics are introduced into practice: fluoroquinolones, antiviral drug of azoloazine series triazavirin, new antitumor drug lysomustine.